Esperion Therapeutics Inc. appointed Jay Shepard as a class III director, with a term expiring at the company's 2019 annual meeting of stockholders.
Shepard has served as the president and CEO of Versartis Inc. since May 2015.
Ann Arbor, Mich.-based Esperion Therapeutics is a lipid management company, which focuses on developing and commercializing oral therapies to treat elevated low-density lipoprotein cholesterol.
